Pancreatic cancer is one of the deadliest forms of cancers and has a high mortality rate of 93 percent among patients diagnosed within five years; half of whom die within weeks to months. By 2020, it will be the second most deadly cancer, after lung cancer. Needless to say pancreatic cancer research receives less than 2 percent in funding in Canada.
As a not-for-profit organization, the Cancer Research Society has for years allocated funding to support cancer research throughout the country. This partnership with Pancreatic Cancer Canada will ensure that funding is provided to researchers of pancreatic cancer. Funding PancOne™ research will institute ground breaking development into pancreatic cancer drugs, improve early detection and ultimately increase overall pancreatic cancer survival rates.